CA Ventures Plans $500 Million Investment in European Housing
Chicago-based CA Ventures today announced plans to invest $500 million over the next five years in the European housing market, specifically across the purpose-built student housing and multifamily apartment sectors.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180227006503/en/
ARC at Old Colony (Chicago): CA Ventures transformed an existing office building into a 384-bed student housing community serving Illinois’ largest concentration of urban college campuses. (Photo: Business Wire)
A vertically integrated owner, developer and operator of apartments spanning all adult life stages, CA Ventures has a $6.7 billion portfolio comprising student housing, multifamily and senior living communities throughout the United States. Over the last eight years, the firm’s student housing entity, CA Student Living, has amassed a $3 billion portfolio serving over 40 universities in the U.S., Canada, Latin America and, now, Europe. During that same period, CA successfully sold over $2.5 billion of student accommodation assets. The firm’s strategy is to deliver highly amenitized, best-in-class near-campus properties in leading university markets, both nationally and internationally, where enrollments have increased and the housing supply has not kept pace.
“CA has been an innovator in student housing in the Americas for over a decade and, as a team, we’ve been evaluating the European housing market closely for several years,” said Tom Scott, CEO of CA Ventures. “We believe the market for purpose-built student housing in Europe is poised to benefit from growing university enrollments, increasing consumer adoption and a very limited supply of amenitized housing. As we are more than just capital, our capabilities as a vertically integrated developer and operator uniquely position us to bring our successful model to Europe, capitalizing on the scale and depth of these markets.”
The firm is currently developing two student housing projects in Poland – 700 beds in Krakow and 400 beds in Warsaw – and is in active negotiations to acquire properties and development sites in the U.K., the Netherlands, Germany, Spain, Ireland and the Czech Republic.
“As a pioneer of pedestrian-oriented, infill high-rise housing proximate to growing university populations, CA has delivered nearly 20,000 purpose-built student housing beds to date,” said JJ Smith, president of CA Student Living. “We have a strong track record of bringing a market-specific curation of building design, unit mix and amenity offerings to underserved university populations in the U.S. and internationally.”
“Across the geographically diverse markets in which we do business, student preferences are actually quite similar despite cultural nuances,” continued Smith. “Today’s students seek modern designs and conveniences such as fully furnished suites, private bedrooms and bathrooms, ample closet storage and a robust combination of well-appointed common spaces for social and academic pursuits. On-site management ties it all together with hands-on programming and a keen eye for safety protocols.”
According to Smith, Poland is a particularly attractive European market with strong enrollment growth from locals as well as students from other countries due to its high-quality, cross-discipline university programs offered in English. CA estimates that while nearly 50 percent of the 2 million university students in Poland do not live with their parents, there are less than 200,000 student housing beds currently available, much of it functionally obsolete.
“Broadly across Europe, less than a third of all students currently live in purpose-built student housing, so we see tremendous runway,” said Smith. “We have spent a significant amount of time researching specific markets, identifying landowners and pinpointing co-development partners looking to parlay their local expertise to a platform that de-risks their position and provides capital alongside design, development, construction management, leasing and operations expertise in the student accommodations sector. Already we have enjoyed great success and this is just the beginning. Our access to capital and ability to handle all aspects of development will allow us to move quickly to secure the best opportunities.”
About CA Ventures:
CA Ventures LLC is a Chicago-based real estate investment holding company whose international portfolio includes $7.8 billion in assets throughout the U.S., Canada and Latin America. While initially focused on student housing, CA Ventures has since diversified into other sectors, including office, senior living, multifamily, and hospitality. In addition to development and renovation, the firm specializes in institutional joint ventures; value add investing; equity and debt sourcing; and asset management services. CA Ventures serves as the holding company for the CA family of companies, including CA Student Living, CA Office / Vanderbilt Partners, CA Senior Living, CA Residential, CA International, and CA Hospitality. For more information, visit www.ca-ventures.com.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i